Exhibit 99.1

News release via Canada NewsWire, Vancouver 604-669-7764

	    Attention Business Editors:
	    Neovasc to Raise $2 Million in Non-Brokered Private Placement

	    <<
	    --Proceeds Will Advance Key New Products Including Completing CE Mark
	    Application for the Reducer(TM) Stent--
	    >>

	    VANCOUVER, March 30 /CNW/ - Neovasc Inc. (TSXV: NVC) today announced that
it intends to undertake a non-brokered private placement of approximately 9.52
million units at the price of $0.21 per unit for aggregate gross proceeds of
$2.0 million. The proceeds of the offering will be used for continued
development of a suite of new products and to help fund continuing operations.
The completion of the private placement is subject to TSX Venture Exchange
approval and the execution of definitive documentation with investors. The
securities issued pursuant to the offering will be subject to a four-month
hold period from the date of issuance. The private placement is led by members
of the Frost Group, LLC.
	    Each unit consists of one common share of Neovasc stock and one-half of
one common share purchase warrant of Neovasc stock. Each whole warrant will
entitle the holder thereof to purchase one common share of Neovasc stock at
the exercise price of $0.30 per share for a period of one year after the
closing date of the offering. All of the proceeds will be placed with company
insiders.
	    "This financing provides us with additional operating flexibility to
advance the products that we expect to be key growth drivers for Neovasc,
especially our innovative Reducer(TM) stent for the treatment of refractory
angina," said Alexei Marko, chief executive officer of Neovasc. "We are
pleased at the confidence in Neovasc evidenced by the participation of
insiders in this financing, which strengthens our ability to execute on the
focused strategy we implemented late last year."

	    About Neovasc Inc.

	    Neovasc Inc. is a new specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing vascular and
surgical marketplace. The company's current products include, Metricath(R) for
intravascular measurement and Peripatch(TM) surgical tissue and staple line
reinforcement products. Neovasc has a development pipeline of innovative new
products, and provides contract medical device development and manufacturing
services. For more information, visit: www.neovasc.com.

	    About Frost Group, LLC

	    The Frost Group, LLC, is a private investment firm based in Miami. The
Frost Group is led by Dr. Phillip Frost, and includes Jane Hsiao, Ph.D., Rao
Uppaluri, Ph.D., and Steven D. Rubin, a team that has been together in various
capacities for over 22 years. Since its formation in October 2006, the Frost
Group has invested over $140 million in various companies and technologies in
the United States and abroad. These investments include stakes in the areas of
pharmaceuticals, diagnostic devices, medical devices, developmental education
and entertainment for children, telecommunications, sports licensing, aviation
services, software for seismic data analysis, and new materials for computer
chips.

	    Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.

	    %CIK: 0001399708

	    /For further information: Corporate contact: Neovasc Inc., Chris Clark,
(604) 248-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners,
Barbara Lindheim, (212) 918-4650/
	    (NVC.)

CO:  Neovasc Inc.

CNW 07:32e 30-MAR-09